CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.41 USD
+1.39 (2.53%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $56.82 +0.41 (0.73%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 41 - 60 ( 207 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Regulatory Submission for Hemoglobinopathy Cure to Begin in November
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Vertexs Acquires ViaCyte. Friend or Foe in Diabetes?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Encouraging Early Responses from AlloCAR-T in T-cell Lymphoma at EHA 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Functional Cure of 75 Patients Having Hemoglobinopathies Presented at Hematology Meeting
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRSP: Responses Seen with the Second AlloCAR-T in T-cell Lymphoma at EHA
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
1Q22: Getting Closer to Commercializing its First Asset
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T